search

Active clinical trials for "Hemophilia A"

Results 281-290 of 769

Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant...

Hemophilia A

This is a clinical study to investigate the pharmacokinetics, efficacy, safety and immunogenicity of human-cl rhFVIII, a newly developed human cell-line derived recombinant FVIII concentrate in previously treated patients with severe Hemophilia A.

Completed6 enrollment criteria

Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects

Hemophilia A

This study will evaluate the safety and efficacy of on-demand treatment with Xyntha in Chinese hemophilia A subjects.

Completed17 enrollment criteria

Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection

Hepatitis CHemophilia

Hemophilic patients are a known high risk groups for acquiring the hepatitis C. The surveillance data from Ministry Of Health in IR.Iran had shown that 60% of them are infected with HCV infection. We are trying the PEGASYS plus Ribavirin in Hemophilic patients with HCV.

Completed15 enrollment criteria

Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980

Hemophilia A

The primary objective of this study is to determine the pharmacokinetic profile after single administration of two doses of BAY 79-4980 (high and low: 35 IU FVIII/Kg reconstituted in 22 mg and 13 mg of liposomes/Kg, respectively) compared to rFVIII-FS (35 IU/Kg reconstituted in 2.5 mL WFI/1000 IU) in PTPs aged 12 to 60 years with severe hemophilia A.

Completed20 enrollment criteria

Russian Kogenate Pediatric Study

Hemophilia A

A prospective study to evaluate the effect of rFVIII-FS in different prophylactic regimens on bleeding events frequency and development of arthropathy in Previously Treated and Minimally treated Hemophilia A pediatric population.

Completed7 enrollment criteria

Phase I/IIa Study of FIXFc in Hemophilia B Patients

Hemophilia B

The primary objective of the study is to assess safety of FIXFc at doses ranging from 1 to 100 IU/kg.

Completed17 enrollment criteria

Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With...

Hemophilia A or B With InhibitorsHemophilia A1 more

The purpose of the study was to determine the efficacy, safety, and health-related quality of life benefits with FEIBA NF prophylactic treatment as compared with on-demand treatment.

Completed25 enrollment criteria

Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B

Congenital Bleeding DisorderHaemophilia B

This trial is conducted in Europe, Japan and the United States of America (USA). The aim of this clinical trial is to investigate the safety and pharmacokinetics (the determination of the concentration of the administered medication in blood over time) of Pegylated Recombinant Factor IX (nonacog beta pegol) in Non-Bleeding Patients with Haemophilia B.

Completed7 enrollment criteria

Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A

Severe Hemophilia A

The purpose of this study is to determine the immunologic and overall safety associated with long-term use of Alphanate in subjects diagnosed with severe hemophilia A (Factor VIII:C less than 0.01 IU/ml), who have been previously treated with plasma-derived Factor VIII products other than Alphanate and who have no history of developing either antibody inhibitors to Factor VIII or nonspecific inhibitors of coagulation.

Completed18 enrollment criteria

Study Evaluating rFIX; BeneFIX® in Hemophilia B

Hemophilia B

The primary objective of this clinical research study is to assess the safety and efficacy of rFIX for a minimum of 6 months in previously treated patients (PTPs) with hemophilia B (FIX:C ≤2%) during standard-of-care treatment (on-demand, prophylaxis, and through major and minor surgical procedures).

Completed6 enrollment criteria
1...282930...77

Need Help? Contact our team!


We'll reach out to this number within 24 hrs